X4 Pharmaceuticals (XFOR) Competitors $1.89 -0.01 (-0.53%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XFOR vs. GNTA, PMVP, VRCA, ZIVO, CNTB, IRD, KRON, NRXP, IFRX, and MGXShould you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Genenta Science (GNTA), PMV Pharmaceuticals (PMVP), Verrica Pharmaceuticals (VRCA), ZIVO Bioscience (ZIVO), Connect Biopharma (CNTB), Opus Genetics (IRD), Kronos Bio (KRON), NRx Pharmaceuticals (NRXP), InflaRx (IFRX), and Metagenomi (MGX). These companies are all part of the "pharmaceutical products" industry. X4 Pharmaceuticals vs. Its Competitors Genenta Science PMV Pharmaceuticals Verrica Pharmaceuticals ZIVO Bioscience Connect Biopharma Opus Genetics Kronos Bio NRx Pharmaceuticals InflaRx Metagenomi Genenta Science (NASDAQ:GNTA) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment. Which has more volatility & risk, GNTA or XFOR? Genenta Science has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Does the media favor GNTA or XFOR? In the previous week, Genenta Science and Genenta Science both had 2 articles in the media. Genenta Science's average media sentiment score of 0.94 equaled X4 Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is GNTA or XFOR more profitable? X4 Pharmaceuticals has a net margin of 46.54% compared to Genenta Science's net margin of 0.00%. Genenta Science's return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Genenta ScienceN/A N/A N/A X4 Pharmaceuticals 46.54%-181.56%-54.36% Which has preferable valuation and earnings, GNTA or XFOR? Genenta Science has higher earnings, but lower revenue than X4 Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenenta ScienceN/AN/A-$9.64MN/AN/AX4 Pharmaceuticals$2.56M4.27-$37.45M$2.140.88 Do analysts prefer GNTA or XFOR? Genenta Science currently has a consensus target price of $25.00, indicating a potential upside of 691.14%. X4 Pharmaceuticals has a consensus target price of $72.33, indicating a potential upside of 3,727.16%. Given X4 Pharmaceuticals' higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Genenta Science.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in GNTA or XFOR? 15.1% of Genenta Science shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 2.2% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryGenenta Science and X4 Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks. Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XFOR vs. The Competition Export to ExcelMetricX4 PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.91M$2.88B$5.52B$8.87BDividend YieldN/A2.70%5.36%4.13%P/E Ratio0.8821.6626.5019.82Price / Sales4.27267.10410.19110.66Price / CashN/A41.2925.8827.49Price / Book0.487.277.945.39Net Income-$37.45M-$55.05M$3.15B$248.34M7 Day Performance-17.83%-0.47%1.08%1.25%1 Month Performance-43.92%6.59%5.34%5.41%1 Year Performance-89.31%0.42%32.80%18.07% X4 Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XFORX4 Pharmaceuticals4.8107 of 5 stars$1.89-0.5%$72.33+3,727.2%-89.1%$10.91M$2.56M0.8880GNTAGenenta Science2.3053 of 5 stars$3.06flat$25.00+717.0%-1.6%$55.97MN/A0.007News CoveragePositive NewsGap DownPMVPPMV Pharmaceuticals2.9876 of 5 stars$1.07-1.8%$5.50+414.0%-34.6%$55.59MN/A-0.9150Positive NewsVRCAVerrica Pharmaceuticals4.0406 of 5 stars$0.59+0.4%$8.00+1,262.2%-92.7%$54.32M$7.18M-0.4940News CoveragePositive NewsGap UpZIVOZIVO Bioscience0.3517 of 5 stars$14.22flatN/AN/A$54.22M$15.85K-2.9110CNTBConnect Biopharma3.7869 of 5 stars$0.98-5.3%$7.00+617.9%-35.5%$54.17M$26.03M0.00110Positive NewsGap UpIRDOpus Genetics1.8331 of 5 stars$0.91-4.6%$7.33+709.2%N/A$54.06M$10.99M-0.4314Analyst DowngradeGap DownKRONKronos Bio3.6668 of 5 stars$0.88+1.5%$1.63+84.7%-29.0%$53.72M$9.85M-0.82100Positive NewsNRXPNRx Pharmaceuticals2.027 of 5 stars$3.10-4.9%$28.50+819.4%+33.6%$53.60MN/A-1.542IFRXInflaRx3.1068 of 5 stars$0.79-0.3%$6.60+732.3%-54.6%$53.24M$129.75K-0.9760MGXMetagenomi2.5364 of 5 stars$1.42-2.1%$13.00+815.5%-63.7%$53.08M$52.29M-0.67236Positive News Related Companies and Tools Related Companies GNTA Competitors PMVP Competitors VRCA Competitors ZIVO Competitors CNTB Competitors IRD Competitors KRON Competitors NRXP Competitors IFRX Competitors MGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XFOR) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredFine. Don’t believe me. They called me an alarmist... When in 2010 I said America’s debt was out of control. When I warned it w...Porter & Company | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
